Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive…

The following two tabs change content below.
PLoS Medicine

PLoS Medicine

PLOS (The Public Library of Science) is a non profit publisher and advocacy organization on a mission to lead a transformation in research communication. From its start, PLOS has engaged in debate about science and medicine. Content from PLoS is shared via RSS through GHHub using the Creative Commons. http://www.plosmedicine.org/

by Mark A. Boyd, Amanda Mocroft, Lene Ryom, Antonella d’Arminio Monforte, Caroline Sabin, Wafaa M. El-Sadr, Camilla Ingrid Hatleberg, Stephane De Wit, Rainer Weber, Eric Fontas, Andrew Phillips, Fabrice Bonnet, Peter Reiss, Jens Lundgren, Matthew Law Background The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study has developed predictive risk scores for cardiovascular disease (CVD) and chronic kidney disease (CKD, defined as confirmed estimated glomerular filtration rate [eGFR] ≤ 60 ml/min/1.73 m2) events in HIV-positive people. We hypothesized that participants in D:A:D at high (>5%) predicted risk for both CVD and CKD would be at even greater risk for CVD and CKD events.

Read the article:  

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive…